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Background: Several pre-erythrocytic malaria vaccines based on the circumsporozoite protein (CSP) antigen of
Plasmodium falciparum are in clinical development. Vaccine immunogenicity is commonly evaluated by the
determination of anti-CSP antibody levels using IgG-based assays, but no standard assay is available to allow
comparison of the different vaccines.
Methods: The validation of an anti-CSP repeat region enzyme-linked immunosorbent assay (ELISA) is described.
This assay is based on the binding of serum antibodies to R32LR, a recombinant protein composed of the repeat
region of P. falciparum CSP. In addition to the original recombinant R32LR, an easy to purify recombinant
His-tagged R32LR protein has been constructed to be used as solid phase antigen in the assay. Also, hybridoma cell
lines have been generated producing human anti-R32LR monoclonal antibodies to be used as a potential
inexhaustible source of anti-CSP repeats standard, instead of a reference serum.
Results: The anti-CSP repeats ELISA was shown to be robust, specific and linear within the analytical range, and
adequately fulfilled all validation criteria as defined in the ICH guidelines. Furthermore, the coefficient of variation
for repeatability and intermediate precision did not exceed 23%. Non-interference was demonstrated for
R32LR-binding sera, and the assay was shown to be stable over time.
Conclusions: This ELISA, specific for antibodies directed against the CSP repeat region, can be used as a standard
assay for the determination of humoral immunogenicity in the development of any CSP-based P. falciparum malaria
vaccine.
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ValidationBackground
Malaria, due to infection by the protozoan genus Plasmo-
dium, is a major cause of morbidity and mortality world-
wide, being responsible for 655,000 [1] to 1,238,000 [2]
deaths a year in 2010, mostly children in sub-Saharan
Africa. In addition to the existing prevention and control
measures, malaria vaccines are considered the most* Correspondence: pierre.cambron@gsk.com
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reproduction in any medium, provided the orpromising approach for the prevention of malaria disease
and death, and the World Health Organization has refer-
enced up to 23 malaria vaccine projects under clinical de-
velopment [3]. The RTS,S vaccine candidate, based on
circumsporozoite protein (CSP) sequences of Plasmodium
falciparum (for review, see [4]), is the most advanced
among these and is currently engaged in a large scale
phase III clinical trial program [5,6].
Specific anti-CSP IgG levels are a relevant parameter
in CSP-based malaria vaccine projects, as there is evi-
dence from preclinical models that anti-CSP antibodiesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pre-erythrocytic stage of the disease [7-11]. In line with
this, an association between anti-CSP antibody levels
and protection against P. falciparum infection or clinical
malaria disease has been observed in humans participa-
ting to RTS,S-based vaccine trials [12-20]. It has been
suggested that opsonization of the sporozoites by anti-
CSP antibodies is at least one of the mechanisms indu-
cing protective immunity [21].
The Asn-Ala-Asn-Pro (NANP) sequence is the major
B-cell epitope of the P.falciparum CSP [22], and NANP-
based peptides have already been widely used in immuno-
assays aimed at detecting anti-CSP antibodies [23-26]. Re-
combinant proteins composed of 15 NANP repeats and an
Asn-Val-Asp-Pro (NVDP) oligopeptide, NVDP(NANP)15,
30 NANP repeats, [NVDP(NANP)15]2, or 45 NANP
repeats, [NVDP(NANP)15]3, were shown to induce anti-
bodies that bind to the natural CSP on P. falciparum
sporozoites and to block the invasion of human hepatocytes
by the parasite [27,28].
The present report describes an enzyme-linked im-
munosorbent assay (ELISA) for the evaluation of the im-
munogenicity of CSP-based P. falciparum malaria vaccine
candidates, relying on the quantification of human IgG
directed against NANP epitopes. R32LR, a recombinant
protein consisting of two NVDP oligopeptides and 30
NANP repeats linked to the dipeptide Leu-Arg [NVDP
(NANP)15]2LR [29,30], was used as coating antigen. The
ELISA has been validated according to ICH guidelines
[31] and has demonstrated precision, linearity, specificity,
robustness, non-interference and stability. Furthermore,
a new His-tagged R32LR antigen and a human anti-
R32LR monoclonal antibody have been generated,
which could extend the operational lifetime of this anti-
CSP repeats ELISA.
Methods
Coating antigen
R32LR
R32LR is a recombinant protein produced in AR58
Escherichia coli strain with a temperature induction
process and purified by three precipitation steps, fol-
lowed by reversed-phase high performance liquid chro-
matography and size-exclusion chromatography, as already
described [29]. The final sample buffer was 0.2 M phos-
phate buffer, pH 6.5. The protein was stored in aliquots
at -80°C until use.
His-R32LR
His-R32LR was constructed with six histidine residues
at the N-terminus. Briefly, a plasmid encoding an E. coli
codon-optimized R32LR DNA sequence preceded by
a histidine-tag was obtained from GENEART AG
(Regensburg, Germany). His-R32LR was subcloned in apET29a plasmid by insertion between NdeI and SacI
sites, and transformed in the BLR(DE3) E. coli strain.
Expression of the recombinant protein was obtained
by addition of isopropyl β-D-1-thiogalactopyranoside
(1 mM) before the temperature was shifted to 39.5°C
for 4 h. For purification purpose, bacterial cells were
grown in fermenter using fed-batch method and the
same induction strategy. The bacterial pellet was sus-
pended in 50 mM phosphate buffer, pH 7.5 containing
300 mM NaCl, 5% glycerol (v/v), 0.1% sodium deoxy-
cholate (w/v), supplemented with complete protease in-
hibitor cocktail (Roche, 1 tablet/50 ml buffer). The cells
were lysed by three French press extractions at 15,000
psi. After refrigerated centrifugation for 30 min at
17,400 × g, the supernatant was harvested and filtered
through a 0.22-μm membrane.
His-tagged R32LR was further purified through a nickel
column (Ni NTA superflow, Qiagen) with elution by imi-
dazole gradient. The pooled positive fractions were dia-
lysed against 50 mM Tris, pH 7.5, containing 5% glycerol
(v/v) and subjected to ion-exchange chromatography
(Mono-Q column, Pharmacia). The positive fractions were
pooled and dialysed against 10 mM phosphate buffer, pH
6.6, containing 150 mM NaCl. R32LR (and His-R32LR) is
neither detected by Coomassie blue nor by UV absorbance
at 280 nm [29], but high-performance liquid chroma-
tography coupled with detection at 205 nm was used to
control batch homogeneity. Protein purity was evaluated
by Coomassie blue-stained electrophoresis gel to visualize
any contaminating protein, and on western blot mem-
brane probed with rabbit anti-serum targeting E. coli
lysate proteins. Protein identity was evaluated by western
blotting using a murine monoclonal antibody recognizing
NANP (in-house; R3G12 antibody). Endotoxin concentra-
tion in the final product was determined by Limulus
amoebocyte lysate -kinetic QCL assay (Cambrex). R32LR
and His-R32LR concentrations were determined by dosage
of total nitrogen content. Briefly, after pyrolysis, nitrogen
compounds were converted into nitrogen monoxide which
then reacted with ozone to produce NO2*. NO2* emitted a
photon which was detected after signal amplification in an
Antek 9000 device (Alytech, France). After purification,
both antigens were kept in aliquots at -80°C.
Serum samples
The assay was developed by using serum samples from
healthy subjects in different clinical trials, and taken at
various time points after vaccination with RTS,S. RTS,S
is composed of a polypeptide chain of 19 NANP repeats
and a C-terminal region of P. falciparum (3D7) CSP
encompassing amino acids 207–395, fused to hepatitis B
surface antigen (HBsAg), and an unfused (S) polypeptide
of 226 amino acids of HBsAg, spontaneously forming a
virus-like particle [4,32,33].
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healthy adults living in malaria non-endemic areas and
who were thus considered as anti-CSP repeats antibody
seronegative. Positive control samples were pools of
post-vaccination serum samples.
As no international standard preparation is available
for the determination of anti-CSP repeats antibody con-
centration in serum, a human sample from the recipient
of an exploratory malaria vaccine was taken to constitute
the reference standard for the assay, to which a concen-
tration of 109 ELISA units per ml (EU/ml) was attribu-
ted (IR2 reference standard, kindly provided by the
Walter Reed Army Institute of Research). All study par-
ticipants and serum donors have given written informed
consent for the use of their serum for anti-CSP repeats
test development.
Reference human monoclonal antibody
Hybridomas producing anti-R32LR antibodies were gen-
erated using a method described previously [34]. In brief,
human peripheral blood mononuclear cells (PBMC) col-
lected from an individual vaccinated with the RTS-S
vaccine candidate were injected in the spleens (1-2 × 107
cells per animal) of three SCID mice (C.B-17 Prkdcscid/
Prkdcscid). Six days later the mice were bled and their
plasma anti-R32LR antibodies were measured using the
in-house ELISA. On day 7, the mouse displaying the high-
est anti-R32LR concentration was sacrificed, the spleen
was removed and a cell suspension was prepared. Human
PBMC-SCID spleen cells were mixed with K6H5/B5
heteromyeloma cells at a 5:1 ratio, and polyethylene gly-
col 1500 (50% v/v; Boehringer Mannheim, Mannheim,
Germany) was added for 2 min before being washed away.
Fused cells (5 × 104) were cultured in microtiter plate
wells in 200 μl of medium supplemented with human
recombinant insulin (10 μg/ml, Boehringer Mannheim),
ouabain (1 μM, Sigma, St. Louis, MO), hypoxanthine-
aminopterin-thymidine (Life Technologies, Belgium) and
10% v/v BM Condimed HI (Boehringer Mannheim). Cul-
tures were replenished with fresh medium every other day
and individual wells were checked for cell growth first and
anti-CSP antibody production subsequently. Seven anti-
R32LR antibody-producing cultures were selected, sub-
cloned and further expanded.
The seven hybridomas, producing anti-R32LR IgG1,
were cultured in CELLine 1000 (Integra Bioscience,
Chur, Switzerland), a membrane based disposable cell
culture system. For optimal production level the device
was inoculated with 50 × 106 cells in Dulbecco’s modi-
fied Eagle medium at high glucose concentration supple-
mented with glutamine, sodium pyruvate, essential and
non-essential amino acid, a cocktail of antibiotics and
5% fetal bovine serum. Eighty percent of the productionmedium and the entire nutrition medium were changed
twice a week.
Systems were stopped after 37 days of culture includ-
ing preculture phase, and 2 hybridomas (MAL 1C and
MAL 2A) showed a productivity of 19 mg/month/150
million cells. Monoclonal antibodies were purified by af-
finity chromatography on Protein A-sepharose Fast Flow
(GE Healthcare), aliquoted and stored in phosphate-
buffered saline at -20°C before being used as standard in
anti-CSP repeats ELISA.
R32LR ELISA
IgG antibodies directed against the CSP repeat region were
measured as follows. R32LR was coated (100 μl/well of a
solution of 1.25 μg/ml prepared in 0.05 M carbonate/bicar-
bonate buffer, pH 9.4-9.8) onto a 96-well polystyrene plate
(F96 MaxiSorp, Nunc) for 14-16 h at 5 ± 3°C. After coating,
plates were washed 3 times with phosphate-buffered saline
(PBS), pH 7.4, supplemented with 0.1% Tween-20 (v/v;
Sigma, ref P1379). Nonspecific binding sites were satura-
ted with 200 μl/well of blocking buffer, consisting of
PBS (pH 7.4) containing 0.1% Tween-20 (v/v) and 0.5%
skimmed milk (Becton Dickinson, ref 232100), for 2 h at
room temperature (RT) on an orbital shaker. No washing
step occurred after blocking but the plate was turned up-
side down to remove blocking buffer, and gently tapped
down on clean blotting paper. Then, eight serial twofold
dilutions of standard, controls and samples were added
(100 μl/well) and incubated for 2 h at 37°C.
The plates were washed thrice before peroxidase-
conjugated anti-human IgG rabbit antibody (Dako, ref
PO214) diluted in blocking buffer was added for 30 min
incubation at RT. After another washing step, the
chromogen substrate mix was added and incubated for
30 min at RT. The chromogen substrate mix was pre-
pared extemporaneously and consisted of four volumes of
substrate buffer [Na2HPO4 (Merck 1.06586), citric acid
(Merck 1.002441000) supplemented with 0.006% H2O2
(v/v) and adjusted to pH 4.1-4.5] mixed with 1 volume of
3,3’,5,5’-tetramethylbenzidine solution (Sigma, ref T-0440).
The colorimetric reaction was stopped by the addition of
50 μl of 1 N sulphuric acid, before reading the assay plate
at 450 nm in a microtiter plate reader.
An un-weighted 4-parameter logistic (4-PL) fitting al-
gorithm [35] was applied to the standard curve, allowing
the determination of antibody concentration in the sam-
ples, expressed in ELISA Units per milliliter (EU/ml).
Anti-hepatitis B antigen ELISA
Anti-HBsAg antibodies were quantified using Abbott’s
AxSYM Micro-particle Enzyme ImmunoAssay (MEIA)
platform with the dedicated reagent-pack AUSAB, using
a standard curve as described by the manufacturer.
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For the validation of the assay, the following parameters
were evaluated according to the The International Confe-
rence on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH)
guidelines: precision, linearity, specificity, robustness,
interference and stability. Accuracy could not be deter-
mined, as no reference analyte of known purity is avail-
able. Furthermore, the proposed ELISA could not be
compared with another well-characterized gold-standard
assay, as no such assay is available.
Precision
Precision can be defined as the closeness of agreement
between independent test results obtained under stipu-
lated conditions, called intermediate precision and re-
peatability conditions. Intermediate precision expresses
the precision obtained under conditions mimicking the
routine assay conditions. Repeatability expresses the pre-
cision under minimal variable conditions. For the deter-
mination of repeatability and intermediate precision in
the ELISA, 12 serum samples from RTS,S-vaccinated
subjects spanning a large range of anti-CSP repeats anti-
body concentrations were used, measured in duplicate
by three different operators on four different days,
equivalent to 288 measurements. For the determination
of repeatability, every sample was tested in duplicate on
the same plate.
Precision was considered acceptable if it was in line
with the descriptive statistics derived from our in-house
database compiling repeatability and intermediate preci-
sion for 138 ELISAs over the last five years, with appli-
cation of the same experimental design, that is: the 90th
percentile of coefficient of variation (CV) are 12.93% for
repeatability and 31.92% for intermediate precision,
respectively.
Linearity
The linearity of an analytical procedure is defined as its
ability (within the analytical range) to provide a measure-
ment directly proportional to the analyte concentration.
Linearity is confirmed if the degree of underestimation
and overestimation does not exceed 20%. Sixty sera
from RTS,S-vaccinated subjects, of pre-defined anti-CSP
repeats antibody concentration, were used. Sera with a
high anti-CSP repeats antibody concentration were pre-
diluted in order to obtain a concentration situated in the
upper part of the standard curve. All samples were serially
diluted twofold in the microtiter plate. The last dilution
step for each sample was expected to give an anti-CSP
repeats concentration situated in the lower part of the
standard curve. Then, anti-CSP repeats antibody concen-
tration in all serially diluted samples was measured
according to the assay procedure.Specificity
The specificity is the ability to assess unequivocally the
analyte in the presence of components that may be
expected to be present. Two types of experiments were
conducted to assess the specificity of the proposed
ELISA. First, the specificity was investigated by testing 14
serum samples from individuals naïve for malaria but vac-
cinated with HBsAg [36] to demonstrate that the ELISA
does not detect any anti-HBsAg IgG. Second, a competi-
tion experiment with AMA-1 (Plasmodium falciparum
apical membrane antigen-1, kindly provided by the Walter
Reed Army Institute of Research), HBsAg, and R32LR was
conducted. The sera containing specific anti-CSP repeats
antibodies were pre-mixed with either of these antigens
(final concentration: 10 μg/ml in blocking buffer) and
incubated for 24 h at room temperature before being pro-
cessed further according to the assay procedure.
Robustness
The robustness of an analytical procedure is the measure
of its capacity to remain unaffected by small but delibe-
rate variations in method parameters, which provides
indication of its reliability during normal usage. First,
three timings for the coating with R32LR were evaluated:
14, 16 and 18 h (standard timing being 16 h). Second,
the impact of freeze-thaw cycles from -80°C to room
temperature of the coating antigen R32LR was assessed
by evaluating the anti-CSP repeats geometric mean con-
centration and intermediate precision after 1, 2 and 3
freeze-thaw cycles.
Interference
Interferences are defined as artefactual increase or de-
crease in apparent concentration of an analyte due to the
presence of a substance or a treatment.
Analyte stability at various temperatures and impact of
freezing/thawing cycles
Ten samples from RTS,S-vaccinated subjects were sub-
jected to the following conditions: overnight storage at
-20°C, or 3 cycles (24 h duration each) of freeze-thawing
(-20°C to RT), or storage at room temperature for 24 h,
before anti-CSP repeats ELISA.
Heat-inactivation of the serum samples
The effect of complement-inactivation on the measure-
ment of CSP repeats-specific IgG concentration was
assessed on 100 sera (30 negatives, 70 positives). Each of
the 100 sera tested was divided equally into two vials,
one for control and one for heat-inactivation. Paired
samples were tested by the same operator but on differ-
ent days. Complement-inactivation consisted of incuba-
tion at 56°C during 30 minutes.
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To evaluate the stability of the anti-CSP repeats ELISA,
two samples (a low-concentration positive control and a
high-concentration positive control, prepared by pooling,
homogenizing and aliquoting samples previously demon-
strated to be positive) were tested in each plate on every
run performed by the laboratory since the start of the rou-
tine testing in 2007. The limits of these controls were
computed on log10-transformed concentrations using a
minimum of 40 independent values.
To complete the assessment of the stability of the anti-
CSP repeats ELISA, an additional internal blind profi-
ciency panel consisting of 50 samples that have been
previously tested has been re-analysed every six months,
starting in 2008.
Determination of assay characteristics
The calculation of the limit of detection (LOD) and the
limit of quantification (LOQ) was based on a methodology
from The Centers for Diseases Control and Prevention
[37]. Each standard curve was fitted using a four para-
meters logistic (4PL) and the 95% confidence interval
(95% CI) was considered. For a standard curve, the LOD
is the concentration corresponding to the interpolated
intersection of the upper 95% CI of the lower asymptote
with the 4-PL fit of standards data. The LOQ is the con-
centration corresponding to the interpolated intersection
of the upper 95% CI of the lower asymptote with the lower
95% CI of the 4-PL fit of standards data. LOD and LOQ
were computed for each curve and 95th percentile of
LODs and 95th percentile of LOQs were assimilated
respectively as the final LOD and the final LOQ.
The cut-off of the ELISA was based on the upper limit
of the 99.9% one-sided confidence interval of the anti-CSP
repeats response in a naïve malaria-population. The ex-
periment was performed on 108 serum samples obtained
from healthy adults living in a non-endemic malaria
region, hence assumed not to contain anti-CSP repeats
antibody. The log10 -transformed optical density (OD) cor-
responding to the first dilution of each sample were aver-
aged and the standard deviation was determined. In order
to get a value in ELISA Units/ml, the upper limit of the
one-sided 99.9% confidence interval of the mean was
interpolated from the 4PL function built on the average
ODs of the standard curves incubated on the 20 plates.
Finally this value was multiplied by 50, the minimum dilu-
tion factor of the sample.
For the assessment of the analytical range, the lower
limit was set at the LOQ and the upper limit was defined
as the upper limit of linearity.
Statistical analysis
Statistical analyses were performed on log10-transformed
data.For the validation of assay precision, analysis of variance
was performed on the transformed data by using the
MIXED procedure of the SAS system, with all factors con-
sidered as random. Computations were done on the trans-
formed values but the variability in terms of CV was
expressed relative to the non- transformed concentrations.
For linearity, the ratio between successive dilutions
was evaluated for each sample. This ratio was estimated
by linear regression and computed from the slope of this
regression (log (concentration) versus log (dilution)).
These ratios were summarized by calculating the 5th per-
centile, median and 95th percentile.
To evaluate the effect of three freeze-thaw cycles or
the effect of 24 h storage at room temperature, analysis
of variance was performed by using the MIXED proced-
ure of the SAS system, with the factor condition consi-
dered as fixed. The heat-inactivated condition was
compared with the non-inactivated condition by means
of a paired t-test.
The robustness of the assay was evaluated by analysis of
variance using the MIXED procedure of the SAS system,
with the factor incubation considered fixed, for the effects
of coating time. To study the conditions of storage of the
coating antigen, analysis of variance was used (MIXED
procedure of the SAS system) with the factor condition
considered fixed, followed by one-sided Dunnett test. The
effect of sample inactivation was analysed using a con-
cordance analysis, Deming regression [38-40] and corre-
lation analysis.
Stability was evaluated using on the one hand two
positive controls and on the other hand a blind profi-
ciency panel of 50 samples. The quality control (QC)-
specifications of each of the two controls were defined
by computing standard deviation through all data and
uncertainty of the mean was taken into account with an
alpha risk set at 1% for each of the two positive controls.
The stability results using the panel of 50 samples were
analysed with a Deming’s regression and a concordance
analysis.
Results
Assay characteristics
The LOD was estimated at 0.17 EU/ml, rounded off to
0.2 EU/ml and the LOQ was estimated at 0.31 EU/ml
rounded off to 0.3 EU/ml.
The cut-off of the ELISA, to allow the distinction be-
tween anti-CSP repeats negative and positive samples,
was calculated from 108 serum samples from malaria-
naïve individuals and estimated at 0.49 EU/ml, rounded
off to 0.5 EU/ml.
For the analytical range, the lower limit was set at the
limit of quantification, i.e. 0.3 EU/ml. The upper limit
corresponded to the upper limit of linearity, found to be
2440 EU/ml (see below).
Table 1 Intermediate precision and repeatability results
Sample
Code
Number of
observations
GMC
(EU/ml)
CV between
repeats (%)
CV between
operators (%)
CV between
days (%)
CV between days
& operators (%)
1 24 0.9 7.72 12.77 45.10 45.10
2 24 4.9 2.93 9.80 34.75 34.75
3 24 27.0 2.33 9.30 12.32 13.38
8 24 36.7 2.91 9.67 12.12 13.98
4 24 44.8 3.99 10.47 13.72 15.23
5 24 52.0 1.66 9.56 11.11 13.70
10 24 52.5 3.08 12.98 11.79 16.52
7 24 57.2 3.86 12.01 21.20 23.38
6 24 58.6 3.79 12.43 11.73 15.63
9 24 77.2 4.24 13.02 11.81 16.58
12 24 88.9 9.35 18.68 17.56 22.78
11 24 89.5 4.39 13.18 13.64 18.14
ALL 288 32.0 4.69 12.24 20.56 22.46
CV, coefficient of variation; GMC, geometric mean concentration of replicates.
Overall analysis and analysis by sample.
Table 2 Repeatability and intermediate precision results
on samples with low concentration
Sample
Code
Number of
observations
GMC
(EU/ml)
CV between
repeats (%)
CV between days
& operators (%)
1 6 1.4 9.80 27.15
2 6 2.2 0.00 11.49
4 6 4.3 1.45 14.68
6 6 4.6 3.77 5.19
3 6 5.1 1.67 10.25
5 6 6.0 2.40 13.37
7 6 7.0 2.33 10.83
8 6 11.9 3.94 8.33
ALL 48 4.5 4.21 14.86
CV, coefficient of variation; GMC, geometric mean concentration of replicates.
Overall analysis and analysis by sample.
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Precision
To determine the intermediate precision, serum samples
taken from 12 RTS,S-vaccinated subjects were tested by
different operators on different days. To determine the
repeatability, every sample was tested in duplicate on the
same plate (each combination of factors is repeated).
Results of intermediate precision and repeatability are
shown in Table 1. The intermediate precision CV was
estimated at 22.46% with a repeatability CV of 4.69%.
Examination of the data showed that the samples 1 and
2, with the lowest concentrations, gave the highest CV for
the assay intermediate precision (respectively 45.10% and
34.75%). To investigate further any potential relationship
between low concentration and high CV, a second experi-
ment was conducted using eight samples with low concen-
trations, i.e. ranging from 1.4 EU/ml to 11.9 EU/ml. The
eight samples were assayed in duplicate by three operators;
the operators performed the assay on different days (the
two factors “operator” and “day” are then confounded for
the statistical analysis). Results are shown in Table 2 and
demonstrate that low concentrations were measured with a
similar precision as high concentrated samples (overall CV
= 15% for samples with a low concentration and overall CV
= 22.46% for samples displaying a concentration up to 89.5
EU/ml). These precision data are in line with the require-
ments as defined in the Material and Methods section.
Linearity
Sixty sera from RTS,S-vaccinated subjects, covering a
broad range of anti-CSP repeats antibody concentration
were used. For each sample, the ratio between concen-
trations corrected for dilution and those correspondingto successive dilutions were estimated. The median, the
P5 and the P95 of the 60 computed ratios were respec-
tively 1.002, 0.958 and 1.035.
After three serial dilutions, in 90% of the cases, the
degree of underestimation and overestimation were
not greater than 12.1% [(1-0.879) x 100] and 10.9%
[(1.109-1) x 100], respectively. These data are within
the specifications of +/- 20%.
In this respect these results show that the anti-CSP repeats
ELISA was linear within the set of dilutions used, corre-
sponding to concentrations from 1.1 EU/ml to 2440 EU/ml.
Specificity
Because RTS,S is composed of a P. falciparum CSP re-
gion coupled to HBsAg, RTS,S vaccination induces high
amounts of anti-HBsAg antibodies. Therefore, it was
Table 3 Specificity of anti-CSP repeats ELISA using
hepatitis B-positive, malaria-negative serum samples
Sample
Code
Anti-CSP repeats antibody
concentration (EU/ml)
Anti-HBsAg antibody
concentration (mIU/ml)
1 <0.5 41.5
2 <0.5 22.3
3 <0.5 192.6
4 <0.5 654.2
5 0.5 25.1
6 <0.5 1979.0
7 <0.5 11680.0
8 <0.5 649.5
9 <0.5 5.1
10 <0.5 38.1
11 <0.5 10.7
12 <0.5 138200.0
13 <0.5 509.1
14 <0.5 157.4
CSP, circumsporozoite protein; HBsAg, Hepatitis B surface antigen.
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interfere in the ELISA. Results are shown in Table 3.
Out of 14 samples tested, only one (sample number 5)
gave a positive anti-CSP repeats IgG response, but this
response was equal to the cut-off (0.5 EU/ml). This was
considered as a minor impact considering the impreci-
sion at this level of concentration. Therefore, it could be
concluded that anti-HBsAg antibodies do not interfere
with the results of the anti-CSP repeats ELISA.
Further, a competition experiment was performed in
which serum samples were pre-incubated with AMA-1,
HBsAg, R32LR, or assay diluent (control) before beingTable 4 Specificity of anti-CSP repeats ELISA using sera pre-in
Sample
Code
Concentration of anti-CSP repeats antibody (EU/ml)
Inhibited with:
R32LR AMA-1 HBsAg
1 37 70 69
2 80 134 141
3 56 97 102
4 97 156 160
5 146 249 243
6 51 89 98
7 84 148 167
8 124 213 223
9 121 222 235
Mean
AMA-1, apical membrane antigen-1; CSP, circumsporozoite protein; HBsAg, hepatiti
* control: no inhibitory antigen used (co-incubation with diluent).used in the assay (Table 4). No inhibition was observed
with AMA-1 or with HBsAg, whereas a 50% inhibition
on average was observed with R32LR, which is a further
demonstration of specificity. The similar degree of inhi-
bition (~50%) by the same amount of R32LR (10 μg/ml)
in samples of different serial dilutions suggests that this
limited level of inhibition is independent of the quantity
of antibodies present in the sample (Figure 1).
Robustness
The robustness of the assay was evaluated by varying the
incubation time for antigen coating (Table 5). Three
timings were evaluated: 14, 16 and 18 h, and 16 samples
(2 anti-CSP repeats antibody negative and 14 positive)
were assayed. The overall P value for differences between
the three conditions was <0.0001. There was a significant
difference (P <0.0001; Dunnett’s test) between the stan-
dard condition (16 h) and the prolongation by 2 h of the
coating incubation time. Indeed, the concentration mea-
surements were 13% lower with 18 h antigen coating,
whereas no variation was seen between 14 h and 16 h
of antigen coating. Based on these results, the standard
coating time was set at 14-16 h.
In another series of experiments, the coating antigen was
submitted before coating to three freeze-thaw cycles from
-80°C to room temperature and kept at room temperature
during at least 3 h during each cycle. The anti-CSP repeats
ELISA was then performed on a panel of 120 serum sam-
ples (30 anti-CSP antibody negatives, 90 positives). It was
shown that freeze-thaw cycles and short-term storage at
room temperature did not affect the intermediate precision
or the LOQ of the test. The observed intermediate preci-
sion was estimated at 23.8% and the LOQ was demon-
strated at 0.04 EU/ ml. These results are in line with the
precision and LOQ described earlier.cubated with different antigens
% inhibition
CONTROL* R32LR AMA-1 HBsAg
76 51.3 7.9 9.2
138 42.0 2.9 −2.2
105 46.7 7.6 2.9
162 40.1 3.7 1.2
250 41.6 0.4 2.8
97 47.4 8.2 −1.0
167 49.7 11.4 0.0
217 42.9 1.8 −2.8
222 45.5 0.0 −5.9
45.2 4.9 0.5
s B surface antigen.
1 10 100 
1
10
100
1000
0
20
40
60
80
100
Concentration after inhibition
%Inhibition
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nc
en
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n 
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)
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Figure 1 Specificity demonstrated by inhibition of a serially diluted sample.
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In routine procedure, sera may need to be re-tested, hence
frozen and thawed several times. It is therefore important
to evaluate if the determination of anti-CSP repeats anti-
body concentrations is affected by several freeze/thaw
cycles. The effect of storage at room temperature for 24 hTable 5 Influence of the coating time on IgG
concentration
Sample code Anti-CSP repeats concentration (EU/ml) after
coating during:
14 h 16 h 18 h
1 11.3 11.8 10.8
2 7.9 8.5 7.5
3 156.7 174.0 158.2
4 135.7 139.9 118.5
5 642.3 682.9 595.9
6 701.5 635.6 578.5
7 1322.7 1237.7 1047.1
8 1397.4 1320.0 1157.8
9 1779.5 1617.7 1393.3
10 1315.1 1243.2 1082.1
11 1371.9 1298.5 1107.6
12 1180.9 1108.6 974.7
13 1940.2 1923.2 1564.8
14 2124.0 2126.2 1739.9
GMC 468.66 462.31 401.29
CSP, circumsporozoite protein; GMC, geometric mean concentration.was also assessed (to mimic the long sample handling time
that may occur). The samples could be stored at room
temperature for up to 24 h and they tolerated three freeze-
thawing cycles without being affected for their anti-CSP
repeats IgG concentration (analysis of variance with the
factor condition considered as fixed factor; P=0.92)
(Table 6).
In routine procedure, the complement was not inacti-
vated in the samples. However, it may happen that sera
previously complement-inactivated for other analyses
are subsequently used in the anti-CSP repeats ELISA.
Therefore, it was necessary to ensure that this inactiva-
tion had no impact on the concentration of CSP
repeats-specific IgG. The results showed that comple-
ment inactivation did not affect the ability of the test to
correctly discriminate positive from negative samples,
demonstrating 100% (95% CI: 96.38 – 100.00) agree-
ment; concentrations remained equivalent based on the
geometric mean of the individual ratios (1.01 [95% CI
0.97-1.06]) and on the outcome of the Deming regres-
sion (slope 0.9981 [95% CI: 0.9837 – 1.0128], correl-
ation r = 0.9982) (see Figure 2).
Stability
To assess the stability of the assay, the same low and
high concentration control samples were tested in each
plate of the anti-CSP repeats ELISA. Results are illu-
strated in Figure 3, and it was shown that values were
within QC-specification in 99.81% and 99.34% of cases
for the low and high concentration samples, respectively.
Table 6 Influence of 3 freeze-thaw cycles or storage at
room temperature of the serum sample on anti-CSP
repeats antibody concentration
Sample code Concentration (EU/ml)
Basis
condition
3 cycles RT
1 80.7 74.2 74.5
2 122.2 150.5 139.9
3 92.7 93.0 99.5
4 80.6 80.7 77.4
5 57.2 50.0 68.9
6 68.3 72.4 64.2
7 94.8 89.3 87.0
8 111.0 118.5 112.0
9 41.5 45.2 41.7
10 610.0 596.7 591.7
GMC 97.37 98.57 98.43
GMR, compared with
basis condition (95%CI)
1.01
(0.94-1.09)
1.01
(0.94-1.08)
GMR, geometric mean of the individual ratios.
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http://www.malariajournal.com/content/11/1/384Stability of the ELISA was also demonstrated by using
a blind proficiency panel re-analysed every 6 months
(Table 7).
Production and bridging of His-R32LR
Four hundred milligrams of His-R32LR were obtained
from 30 g of bacterial pellet. After purification byFigure 2 Comparison of heat inactivated samples with non-inactivate
inactivated serum (untreated‘) as a function of inactivated serum samples (
bias - Deming regression represented with ratios (inactivated/untreated) ve
as equal.nickel affinity and ion exchange chromatography, the
purity of His-R32LR was indirectly demonstrated by
the fact that no band was stained by Coomassie blue
after gel electrophoresis. In addition, no band was
detected by western blotting, using antibody directed
against total E. coli proteins. The expected multiband
pattern, corresponding to the profile of the original
R32LR, was seen after western blotting using R3G12
antibody, confirming protein identity. Batch size
homogeneity was confirmed by high-performance li-
quid chromatography, showing a single peak at 205 nm,
and final protein concentration was determined by dosage
of total nitrogen content. Endotoxin concentration was
27.5 EU/ml.
Sample concentrations were equivalent when measured
by the anti-CSP repeats ELISA with either His-R32LR or
the initially used R32LR as coating antigen, which is
demonstrated by the geometric mean of the individual
ratios being 1.02 (95% CI: 1.00-1.04), and the slope and
correlation of the Deming’s regression (Figure 4) being
respectively 0.9854 (95% CI: 0.9766-0.9942) and 0.9993.
The positive/negative agreement (Table 8) was very high
[98.99% (95% CI: 94.50-99.97%) agreement and Mc
Nemar p-value=1,000] with only one sample returning
as false positive result using His-R32LR. However, the
reported concentration of this sample (0.517 EU/ml)
was close to the assay’s cut-off (0.5 EU/ml). It is im-
portant to note that during routine testing, extremely
low titer results (0.5 – 1 EU/ml) are subjected to a con-
firmation (re-testing) procedure.d samples. A, Deming regression (ultrastructural model) of non-
inactivated) where variances are considered as equal. B, Plot of the
rsus inactivated (ultrastructural model) where variances are considered
A
nt
i-C
SP
 re
pe
at
s
(E
U/
ml
)
A
nt
i-C
SP
 re
pe
at
s
(E
U/
ml
)
BA
Figure 3 Stability of quality control samples. A, Stability of the Low Titer Quality control sample measured in each plate of the ELISA run
(with the lower and upper rejection limit). B, Stability of the High Titer Quality control sample measured in each plate of the ELISA run (with the
lower and upper rejection limit).
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The human monoclonal antibodies (MAL 1C and MAL
2A) were tested in the anti-CSP repeats ELISA against the
internal reference in twofold serial dilutions from 1/50
down to 1/1.34 × 1010. Sigmoidal dose range response
curves were obtained for both monoclonal antibodies and
the curves were superimposable to that of the originally
used standard (Figure 5). The obtained OD values within
the analytical range of the ELISA were used to determine
that MAL 1C and MAL 2A represent 11,130.0 EU/ml and
16,372.9 EU/ml of anti-CSP repeats antibody concentration,
respectively. Accordingly, a value of 500 EU/ml in the
current standardization was found equivalent to 16 μg/ml
and 18 μg/ml for MAL1C and MAL2A, respectively. The
variability observed between the different individual con-
centrations from each dilution used to calculate the con-
centration was limited (MAL 1C inter-dilution % CV = 4.9
and MAL 2A inter-dilution %CV = 0.5).
Considering that both preparations displayed anti-
body concentrations 100- to 150-fold higher than theTable 7 Summary of the results obtained with the same serum
Time point 1 T
Slope of the Deming's regressiona 0,99 (0,98-1,00) 1
Bias of the Deming's regressionb OK
GMRc 1,140
Agreement (%)d 100
McNemar p-valuee OK
aSlope must be equivalent to 1.
bBias must be between 0.5 and 2.00 for the whole range.
cGMR must be between 0.80 and 1.25.
dAgreement must be >80%.
eMcNemar value must be ≥0,05.
GMR, geometric mean of the individual ratios.actually used standard and low amount of standard is
needed to perform the anti-CSP repeats ELISA, 1 ml
of one of these monoclonal antibody preparations will
allow the quantification of up to 2.5 million clinical
trial samples.
Discussion
An R32LR-based ELISA that can be used as a standard
anti-CSP antibody assay for clinical malaria studies in-
volving CSP-based P. falciparum vaccine candidates has
been developed and validated. This assay fulfills the ICH
criteria of precision, linearity, stability and robustness
that are adopted by the regulatory authorities for assay
validation [41,42]. The critical validation parameters are
summarized in Table 9. Panels of blinded serum samples
with high and low anti-CSP repeats concentration have
been included in the routine testing since the introduc-
tion of the assay in 2007 [43], and have confirmed that
the test performs within established criteria. In addition,
it has been shown that R32LR coating antigen is stablepanel tested every 6 months
ime point 2 Time point 3 Time point 4
,00 (0,98-1,01) 0,99 (0,97 - 1,01) 1,01 (1,00 - 1,03)
OK OK OK
1,015 1,027 1,03
100 100 98
OK OK 1,000
Figure 4 Comparison of His-R32LR with the original R32LR as coating antigen. A, Deming regression (ultrastructural model) of His-R32LR as
a function of R32LR where variances are considered as equal. B, Plot of the bias - Deming regression represented with ratios (His-R32LR/R32LR)
versus R32LR (ultrastructural model) where variances are considered as equal.
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http://www.malariajournal.com/content/11/1/384and unaffected by several freeze-thaw cycles. Finally, the
operational lifetime of this ELISA is supported by the
development of alternative laboratory-based sources for
the preparation of key reagents.
Measuring vaccine immunogenicity with a unique
validated immunoassay would allow quantitative com-
parisons between P. falciparum CSP-based vaccine can-
didates. The anti-CSP repeat region ELISA described
here is a relevant choice for this purpose. Being the
reference assay for vaccine immunogenicity during the
clinical development of the RTS,S vaccine candidate
[12,19,43-52], it has an extensive track record of use in
adults as well as in the pediatric population. More than
20,000 serum samples from children living in malaria-
endemic areas have been evaluated to date with this
assay. Using a validated immunoassay would also help
to identify the minimum anti-CSP repeats antibody
concentration associated with protection. In this re-
spect, attempts to define correlates of protection have
already been made with the ELISA presented here in theTable 8 Contingency table showing the number of
negative and positive samples depending on the coating
antigen, R32LR or His-R32LR
His-R32LR
Negative Positive Total
R32LR Negative 29 1 30
Positive 0 69 69
Total 29 70 99context of a malaria field trial [19]. One limitation of this
assay might be the absence of the N-and C-terminal parts
of CSP in the recombinant molecule, implying no detec-
tion of antibodies against potential N- and C-terminal
epitopes. However, to date, the only antibodies shown to
neutralize infectivity of sporozoites are those directed
against CSP repeats [22,53], and it is commonly accepted
that the central repeat region of CSP is a major immuno-
dominant epitope [54,55]. This suggests that the levels of
antibodies against the repeat region may represent a
major part of the global anti-CSP response. One may also
argue that the ELISA presented here does not give indi-
cation on the functionality of the antibodies that are
measured. Nevertheless, anti-CSP antibodies are believed
to be functional, as has been reported previously [56-60].
Different multiples of NANP-repeats have been used
in immunoassays, from (NANP)3 to (NANP)40 [23-26].
Although anti-CSP repeats antibodies can be detected
using repeats of different multiples, it has been observed
in a comparative analysis that results of higher multiples
of NANP-repeats better correlated with each other than
with those of lower multiples and that R32LR-based and
(NANP)40-based ELISAs had higher sensitivity than
(NANP)3-based ELISA [24]. Such discrepancy may ori-
ginate from differences in the coating capacity of short
peptides compared to longer ones. Also, the number of
epitopes on low multiple NANP repeats may be limited
and essentially of the linear type, whereas additional
conformational epitopes may arise from the folding of
high multiple NANP repeat peptides. This has to be
emphasized, since the importance of the three-
Anti-CSP repeats
(EU/ml)
Figure 5 Optical density of serial dilutions of the original standard serum obtained from an exploratory malaria vaccine recipient,
compared to the monoclonal MAL2A antibody and the monoclonal MAL1C antibody.
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http://www.malariajournal.com/content/11/1/384dimensional structure of the CSP repeats for antibody
recognition has already been observed [61]. In line with
this, a preliminary comparison of R32LR to short
(NANP)3-6 peptide ELISA did not yield consistent results
for the evaluation of anti-CSP repeats antibody concen-
tration with the ELISA described here, while NANP10
showed better results (unpublished data). Therefore, an
assay with a longer molecule may be superior to uncover
the polyclonal antibody repertoire induced by CSP vac-
cination. In this regard, R32LR may have an extra advan-
tage compared with a long repeat molecule such as
(NANP)40, since it contains the NVDP sequence inTable 9 Critical assay parameters
LOD 0.2 EU/ml
LOQ 0.3 EU/ml
Cut-off 0.5 EU/ml
Precision (CV) 22.46%
Linearity 1.1 - 2440 EU/ml
Analytical range 0.3 - 2440 EU/ml
LOD, limit of detection.
LOQ, limit of quantification.
CV, coefficient of variation.addition to the NANP repeats (as native CSP does),
which may also represent a possible extra epitope [24].
Furthermore, in contrast with R32LR, short NANP
sequences have never been evaluated in the context of
clinical trials.
The advantages of the R32LR-based ELISA have long
been challenged by the limited availability of its key com-
ponent, R32LR, and by the fact that the reference serum
derived from an adult RTS,S recipient is a reagent in lim-
ited amount. To address this issue, a histidine-tagged
R32LR recombinant protein, easy to purify and available in
large amounts, was produced and shown to be equivalent
to R32LR for the use in the anti-CSP repeats ELISA. In
addition, a human monoclonal antibody has been devel-
oped that recognizes epitopes on R32LR. This anti-R32LR
monoclonal antibody will be a useful standard reagent
since it is equivalent to the human anti-CSP positive serum
and can be produced in large amounts. Ultimately, it may
serve as an international standard preparation.
Conclusions
An anti-CSP repeats ELISA for the evaluation of the im-
munogenicity of CSP-based P. falciparum vaccine candi-
dates has been validated. Critical reagents have been
developed to ensure the continuous application of this
Clement et al. Malaria Journal 2012, 11:384 Page 13 of 15
http://www.malariajournal.com/content/11/1/384assay as a standard anti-CSP ELISA. Establishing a
standard immunoassay for the comparison of immune
responses to the various malaria vaccine candidates was
a main goal in the malaria vaccine technology roadmap
[62]. The current report is a step in this direction.
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